Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Array BioPharma Inc
Femme et Homme Max 99 ans
Array BioPharma Inc
MAJ Il y a 4 ans
Phase Ib/II study of efficacy and safety of MEK162 plus panitumumab in adult metastatic colorectal cancer patients with mutant or wild-type RAS tumors
Phase Ib: To estimate the MTD and/or RP2D of MEK162 in combination with panitumumab Phase II: To assess clinical efficacy of the MEK162 and panitumumab combination
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Array BioPharma Inc
MAJ Il y a 4 ans
A Phase Ib/II study of LGX818 in combination with MEK162 in adult patients with BRAF dependent advanced solid tumors
Phase Ib: To estimate the MTD(s) and/or RP2D(s) of oral LGX818 in combination with oral MEK162, and of oral LGX818 in combination with oral MEK162 and oral LEE011 in patients with BRAF V600-dependent ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Array BioPharma Inc
MAJ Il y a 4 ans
This study is designed to assess the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior lines of therapy
Co-primary: • Compare progression-free survival (PFS) in patients treated with carfilzomib + filanesib and single-agent carfilzomib • Compare objective response rates (ORR) in patients with low seru...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Array BioPharma Inc
MAJ Il y a 4 ans
Binimetinib, Encorafenib, And Cetuximab Combined to Treat BRAF-mutant ColoRectal Cancer Combinación de Binimetinib, Encorafenib y Cetuximab para tratar el cáncer colorrectal con la mutante del gen BRAF
Safety Lead-in: Assess the safety/tolerability of the combination of encorafenib + binimetinib + cetuximab Randomized Phase III: Compare the acitivity of encorafenib + binimetinib + cetuximab (Tripl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Array BioPharma Inc
MAJ Il y a 4 ans
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 12 WEEKS OF TREATMENT WITH ARRY-371797 IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO CONVENTIONAL THERAPY
•To compare the efficacy of ARRY-371797 (200 mg q12h and 400 mg q24h) versus placebo in patients with active ankylosing spondylitis (AS). •To evaluate the safety of ARRY-371797 in patients with active...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Array BioPharma Inc
MAJ Il y a 4 ans
A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS INCOMPLETELY RESPONSIVE TO METHOTREXATE
• To compare the efficacy of 3 dose levels of ARRY-438162 (10 mg BID, 40 mg QD, and 20 mg BID) versus placebo, administered over 12 weeks for the treatment of the signs and symptoms of patients with R...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations